Therapeutic Response

EGFR Exon 19 (Deletion) status confers therapeutic sensitivity to Amivantamab in combination with Carboplatin and Pemetrexed in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Rybrevant (amivantamab-vmjw) [package insert]. FDA. The U.S. Food and Drug administration granted approval to amivantamab-vmjw in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.
Rybrevant (amivantamab) [product information]. EMA. The European Medicines Agency (EMA) has authorized amivantamab in combination with carboplatin and pemetrexed for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI).